Logotype for Mildef Group

Mildef Group (MILDEF) Q3 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Mildef Group

Q3 2025 earnings summary

23 Oct, 2025

Executive summary

  • Order intake reached SEK 907 million in Q3 2025, up 119% year-over-year, driven by organic growth and the Roda acquisition, with a record order backlog for 2026.

  • Net sales doubled to SEK 540 million, increasing 116% year-over-year, with organic growth at 36% and acquisition contributing 80%.

  • Strategic contracts secured with FMV (Sweden), Secunet (Germany), NATO NSPA, and Bundeswehr, reinforcing market position.

  • Significant capacity ramp-up underway, including a new production facility in Stockholm/Rosersberg, quadrupling previous capacity.

  • Roda delivered strong order intake and secured its largest-ever contract with Bundeswehr, strengthening its position in Germany.

Financial highlights

  • Adjusted EBITA for Q3 was SEK 84.6 million, up 172% year-over-year, with a margin of 15.7% (up from 12.5%).

  • Gross margin (excluding M&A) reached 53.5%; group gross margin was 45% due to Roda's lower margin.

  • Free cash flow was negative SEK 53.1 million, mainly due to inventory build-up for Q4 deliveries.

  • Book-to-bill ratio at 1.8, reflecting strong demand and future revenue visibility.

  • Net debt/EBITDA improved to 2.6x, with working capital as a percentage of net sales just below 40%.

Outlook and guidance

  • Strong and intensive Q4 2025 expected, with high delivery volumes and improved free cash flow projected for Q1 2026.

  • Continued focus on scaling capacity, process excellence, and maintaining high gross margins.

  • Anticipated margin improvement for Roda and sustained high margins for the core business.

  • Seasonality expected to persist, with Q4 remaining the largest delivery quarter.

  • Defense tech supercycle and digitalization trends expected to drive long-term growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more